Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment
Open Access
- 31 January 2007
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 5 (1) , 124-129
- https://doi.org/10.1016/j.cgh.2006.10.008
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C†Hepatology, 2005
- Pharmacologic Perspectives for Once-Daily Antiretroviral TherapyAnnals of Pharmacotherapy, 2004
- Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3☆Gastroenterology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug ResistanceClinical Infectious Diseases, 2003
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis CGastroenterology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001